

Call for Poster Abstract:

Submit abstract (max. 300 words) for poster presentation on or before 25th November 2018.

Theme:

1. Druggability of molecules from biopharmaceutical perspective
2. Importance of material properties in biopharmaceutical performance
3. *In vitro*, *in silico* and *in vivo* tools for biopharmaceutical risk assessment
4. Designing of drug delivery systems

Send your abstract to:

aapsnipersstudentchapter@gmail.com

(please feel free to seek clarification at aapsnipersstudentchapter@gmail.com)

Registration Details

To be filled and sent to aapsnipersstudentchapter@gmail.com

Dr./Mr./Ms.....

Organization.....

Address.....

Email.....

Contact Details.....

There is no fees but registration is mandatory.

Please register yourself well in advance. On-the-spot registration is also available.

Registration Desk:

Ms. Shamandeep Kaur (M: +91-8427700690)

Ms. Prachi Joshi (M: +91-9044799264)

About  **aaps**® |  **NIPER**
Student Chapter-S.A.S. Nagar

The AAPS NIPER student chapter established in 2007 in Punjab, India, has been excelling in disseminating information relevant to the growth of young pharmaceutical professionals. Starting with 24 members, the chapter now has more than 90 members. The chapter portrays the ideology “of the students, by the students, and for the students.” It strives to fulfill the needs of the students by organizing talk sessions on diverse topics, from scientific advancements to professional development. Driven by a committed and zealous executive student body, the chapter works for the betterment of students, both on and off campus, by organizing community outreach drives and interactive sessions with experienced peers in the scientific field.

Reaching NIPER SAS Nagar

NIPER is located about 250 Km north of Delhi at SAS Nagar (Mohali), Punjab on total area of 130 acres. SAS Nagar is located close to Chandigarh and is well connected by air, train and road.

Arrival by Air:

Chandigarh airport is about 11 km from NIPER SAS Nagar (approximately 20 minutes drive by taxi). More than 11 flights to Chandigarh are available from Delhi.

Arrival by Train:

Chandigarh railway station is about 14 km from NIPER SAS Nagar (approximately 30 minutes by taxi).

Arrival by Road:

NIPER is about 12 km from Chandigarh Bus stand. For details please log on to <http://chandigarhtourism.gov.in/>.

 Bristol-Myers Squibb

 Syngene

One day International Symposium on

Biopharmaceutics and Drug Delivery:

An Industrial Perspective

(for academic researchers only)

30th November, 2018 (Friday)

9.00 am onwards

Organized by:

 **aaps**® |  **NIPER**
Student Chapter-S.A.S. Nagar

Venue:

National Institute of Pharmaceutical Education and Research (NIPER)
S.A.S. Nagar, Mohali, Punjab, India.

Scientific Programme

- **Introduction to Biopharmaceutical Risk Assessment**
Dr. David Good, BMS
- ***In vitro* Assessment: Biopharmaceutical Risk Assessment for Drug Substance & Drug Product**
Dr. Ajay Saxena, BBRC, Syngene
- ***In silico* Assessment: Drug Discovery**
Dr. Ajay Saxena, BBRC, Syngene
- ***In silico* Assessment: Drug Development**
Dr. David Good, BMS
- ***In vivo/ex vivo* Tools to Enable Biopharmaceutical Risk Assessment**
Dr. Devang Shah, BBRC, Syngene
- **Biopharmaceutical Risk Assessment tools in Drug Delivery**
Dr. David Good, BMS

Speakers' Biography



Dr. David Good, Ph.D.

David is Associate Director in Drug Product Science and Technology (DPST) group at BMS in New Brunswick, NJ. His research group is engaged in early formulation development (Phase 1 and 2), biopharmaceuticals risk assessments, elucidation of degradation mechanisms, as well as modeling of product stability and *in vivo* performance. David received his doctoral degree in Pharmaceutics from University of Michigan, USA.



Dr. Ajay Saxena, Ph.D.

Ajay is Lead Investigator in Biopharmaceutics (BPH) department at Biocon BMS Research & Development Centre (BBRC), Syngene International Ltd., Bengaluru. His research group is engaged in preformulation and formulation development for new chemical entities, supporting preclinical and IND enabling toxicology, Phase 1 and Phase 2a studies through oral & parenteral routes of administration. He received his doctoral degree in Pharmaceutics from University of Bradford, UK.



Dr. Devang Shah, Ph.D.

Devang Shah has been associated with BBRC, Syngene International Ltd., for the past 8 years. He and his team provides PK/PD modelling and simulation-based support to discovery programs thereby enabling PK/PD/efficacy Proof-of-Concept (PoC) studies. Predicting human PK and efficacious dose is an important aspect of his job profile. He received his doctoral degree from Institute of Chemical Technology (formerly UDCT), Mumbai, India.

Sponsors



Bristol-Myers Squibb

Bristol-Myers Squibb (BMS) is a differentiated company, led by a unique BioPharma strategy that leverages the reach and resources of a major pharmaceutical company paired with the entrepreneurial spirit and agility of a biotech firm. Every day, BMS works to deliver innovative medicines for patients with serious and life-threatening diseases.

BMS is focused on helping millions of patients around the world in disease areas such as oncology, cardiovascular, immunoscience and fibrosis. Through BMS R&D organization, it has built a sustainable pipeline of potential therapies, and actively partner to access external innovation to broaden and accelerate work.

More details: <http://www.bms.com>

Syngene

Syngene is an internationally reputed contract research and manufacturing organization, which supports R&D programs from lead generation to clinical supplies. Its multi-disciplinary skills in integrated drug discovery and development include capabilities in medicinal chemistry, biology, *in vivo* pharmacology, toxicology, custom synthesis, process R&D, cGMP manufacturing, formulation and analytical development along with Clinical development services.

More details: <http://www.syngeneintl.com>

Biocon Bristol-Myers Squibb Research & Development Center (BBRC)

Syngene has been closely associated with Bristol-Myers Squibb (BMS) since 1998. In 2007, Syngene set up BBRC, a dedicated research facility for BMS to develop integrated capabilities in medicinal and process chemistry, biology, biotechnology, biomarkers, drug metabolism and pharmacokinetics, analytical research, and pharmaceutical development. This facility is the largest research and development centre outside the United States for BMS, housing more than 475 scientists.

More details: <http://www.syngeneintl.com/services/our-dedicated-centers>